摘要
目的:探讨肠道菌群调节剂培菲康在慢性支气管炎缓解期辅助治疗的作用。方法:选择50例慢性支气管炎患者,按随机抽样法将病人分为2组,分别给予培菲康、安慰剂治疗,疗程6个月,于治疗前后观察呼吸道感染发生次数及免疫球蛋白(IgGI、gMI、gA)和CD3、CD4、CD8各项免疫指标的改变。结果:经治疗,培菲康组呼吸道感染发生率由25.0%下降到4.1%,对照组仅由22.7%下降到18.2%,两组具有可比性。培菲康组免疫球蛋白IgA数值有所下降,IgGI、gM、C3数值有所升高,与用药前比较IgG及C3明显升高(P<0.05);培菲康组CD4/CD8之值明显升高(P<0.05),CD4无显著变化(P>0.05),CD8明显降低(P<0.05);对照组用药前后免疫球蛋白(IgGI、gMI、gA)及CD4、CD8、CD4/CD8之值无显著性差异(P>0.05)。结论:肠道菌群调节剂对慢性支气管炎患者有免疫调节作用,对慢性支气管炎急性发作可能起到一定的预防作用。
Objective To investigate the supplementary effect of intestinal tract microbial population moderator （Bifico） on chronic bronchitis. Methods Fifty patients of chronic bronchitis were randomly allocated into two groups, receiving either bifico or placebo respectively for six months. The change of incidence rotes of respiratory tract infection, immunoglobulin（IgG, IgM,IgA） and CIM,CD8 were assessed before and after therapy. Results The incidence rates of respiratory tract infection declined from 25.0% to 4.1% in Bifico group,from 22.7% to 18.2% in the control group. There was a significant difference. In bifico, immunoglobulin IgA slightly decreased, IgG, IgM, C3 slightly increased after treatment, IgG significantly increased （ P 〈 0.05）, C3 appearenfly rised （ P 〈 0.05 ）. The rate of CD4/CD8 increased （ P 〈 0.05 ）, CD4 did not changed （P 〉 0.05）, CD8 significantly declined （P 〈 0.05 ）in bifico; there were no appearenfly changes in the control group before and after therapy. Conclusion Intestinal tract microbial population moderator has a role of immunoloregulation on chronic bronchitis, preventing its acute episde.
出处
《东南大学学报（医学版）》
CAS
2006年第2期95-97,134,共4页
Journal of Southeast University(Medical Science Edition)
